Nurix Doses First Patient in Phase 3 CLL Trial and Closes Roche Deal
Nurix announced the first patient dosing in a registrational Phase 3 trial for bexobrutideg and received a $700 million upfront payment from Roche, bolstering cash reserves to $1.1 billion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed